Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review

Xie,Changqing; Jones,Vovanti  T.

doi:10.3892/ol.2015.4059

Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review

Authors:
- Changqing Xie
- Vovanti T. Jones
View Affiliations

Affiliations: Department of Internal Medicine, Brody School of Medicine, East Carolina University, Vidant Medical Center, Greenville, NC 27834, USA
Published online on: December 24, 2015 https://doi.org/10.3892/ol.2015.4059
Pages: 1512-1516

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare neurological syndrome of the brain, causing symptoms such as headaches, seizures, altered mental status and visual disturbances. The condition is predominantly associated with hypertension, eclampsia, renal impairment, cytotoxic drugs, immunosuppressive agents and molecular targeted agents, but the precise underlying mechanism of RPLS is not fully understood. The present study describes the case of a 65‑year‑old female patient with stage IIA non‑small cell lung cancer who received cisplatin/pemetrexed treatment at the Leo W. Jenkins Cancer Center. Following 3 cycles of this therapy, the patient was referred to the Emergency Department of Vidant Medical Center with an altered mental status, subsequently presenting with epileptic seizures, a fever and a headache. A neurological examination revealed generalized hyperreflexia and paraparesis, with extensor posturing of the bilateral lower extremities. The lumbar puncture and electroencephalography results were normal, but cranial computed tomography (CT) scans revealed attenuation abnormalities in the bilateral parietal region and the left occipital lobe, with suspected metastasis. Cranial T2‑weighted magnetic resonance imaging (MRI) indicated bilateral regions of increased signal intensity in the occipital, temporal and periventricular white matter. The patient was treated with anticonvulsants, steroids and antihypertensive drugs, recovered gradually from the symptoms and regained full consciousness. However, the patient reported residual weakness, presenting with an Eastern Cooperative Oncology Group score of 3, reflective of an inability to independently perform daily activities and self‑care. A brain MRI performed 10 days later demonstrated that the subcortical edema had partially subsided. The patient was discharged on day 15 post‑admission. A follow‑up cranial CT examination 1 month later indicated a partial resolution of the abnormalities. The present report reviews similar associated cases, and also discusses the clinical features and mechanisms underlying RPLS. Although it is typically reversible, RPLS is a serious and potentially life‑threatening adverse condition if left untreated. Early recognition of this condition is crucial for the prompt control of the patient's blood pressure or withdrawal of cytotoxic drugs in order to reverse this syndrome.

View Figures

View References

1	Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL and Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 334:494–500. 1996. View Article : Google Scholar : PubMed/NCBI
2	Chow S, Cheung CS, Lee DH, Howson-Jan K and Xenocostas A: Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide. Leuk Lymphoma. 53:1003–1005. 2012. View Article : Google Scholar : PubMed/NCBI
3	Helissey C, Chargari C, Lahutte M, Ricard D, Vedrine L, Ceccaldi B and Le Moulec S: First case of posterior reversible encephalopathy syndrome associated with vinflunine. Invest New Drugs. 30:2032–2034. 2012. View Article : Google Scholar : PubMed/NCBI
4	Olascoaga Hualde J, Castiella Molins T, Hernández Souto S, Moreno Becerril F, Petri Yoldi ME, de Sagaseta Ilurdoz M and Molina Garicano J: Reversible posterior leukoencephalopathy: Report of two cases after vincristine treatment. An Pediatr (Barc). 68:282–285. 2008.(In Spanish). PubMed/NCBI
5	Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T and Sobue G: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 19:415–417. 1998.PubMed/NCBI
6	Patel A, Ayto R and MacDonald DH: Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma. Br J Haematol. 161:6072013. View Article : Google Scholar : PubMed/NCBI
7	Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V and Gupta RK: L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg. 37:203–205. 2002. View Article : Google Scholar : PubMed/NCBI
8	Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K and Tomoyasu S: Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 82:304–306. 2007. View Article : Google Scholar : PubMed/NCBI
9	Abali H, Eren OO, Dizdar O, Karadağ O, Erman M, Yilmaz A, Uluç K, Erdem I and Türker A: Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leuk Lymphoma. 46:1825–1828. 2005. View Article : Google Scholar : PubMed/NCBI
10	Allen JA, Adlakha A and Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 63:1475–1478. 2006. View Article : Google Scholar : PubMed/NCBI
11	Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, et al: A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 10:602–608. 2014. View Article : Google Scholar
12	Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P and Foran JM: Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol. 12:1327–1329. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yasaki S, Tukamoto Y, Yuasa N, Ishikawa T and Yoshii F: Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer. Rinsho Shinkeigaku. 52:251–256. 2012.(In Japanese). View Article : Google Scholar : PubMed/NCBI
14	Sugimoto S, Yamamoto YL, Nagahiro S and Diksic M: Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats. J Neurooncol. 24:229–240. 1995. View Article : Google Scholar : PubMed/NCBI
15	Edge SB, Byrd DR, Compton CC, et al: Lung. AJCC Cancer Staging Manual (7th). (New York, NY). Springer. 253–270. 2010.
16	Dersch R, Stich O, Goller K, Meckel S, Dechent F, Doostkam S, Weiller C and Bardutzky J: Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin. J Neurol. 260:1406–1407. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zahir MN, Masood N and Shabbir-Moosajee M: Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: A case report. J Med Case Rep. 6:4092012. View Article : Google Scholar : PubMed/NCBI
18	Kwon EJ, Kim SW, Kim KK, Seo HS and Kim Do Y: A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat. 41:53–55. 2009. View Article : Google Scholar : PubMed/NCBI
19	Maeda T, Kikuchi E, Matsumoto K, Yazawa S, Hagiuda J, Miyajima A, Nakagawa K, Fujiwara H, Hoshino H and Oya M: Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient. Int J Clin Oncol. 15:508–511. 2010. View Article : Google Scholar : PubMed/NCBI
20	Rangi PS, Partridge WJ, Newlands ES and Waldman AD: Posterior reversible encephalopathy syndrome: A possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology. 47:586–590. 2005. View Article : Google Scholar : PubMed/NCBI
21	Onujiogu N, Lengyel E and Yamada SD: Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 111:537–539. 2008. View Article : Google Scholar : PubMed/NCBI
22	Paul F, Aktas O, Dieste FJ, Kreitsch P, Vogel HP and Zipp F: Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil. Nervenarzt. 77:706–710. 2006.(In German). View Article : Google Scholar : PubMed/NCBI
23	Nomura K, Ohno R, Hamaguchi K, Hata T, Hatanaka H and Matsuyama H: Clinicopathological report of cisplatin encephalopathy. Rinsho Shinkeigaku. 35:64–69. 1995.(In Japanese). PubMed/NCBI
24	Perloff D: Hypertension and pregnancy-related hypertension. Cardiol Clin. 16:79–101. 1998. View Article : Google Scholar : PubMed/NCBI